

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Recent Advances in Controlling Cardiacmyocyte Differentiation from Embryonic Stem Cells

Dong-Bo Ou¹, Qiang-Sun Zheng¹, Yong He, Di Zeng and Ji-Wei Teng
Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi' an China

1. Introduction

As a high proliferative ability cell line, embryonic stem (ES) cells can be propagated in undifferentiated state, while maintaining their pluripotency to form various kinds of adult tissue cells (Thomson et al., 1998). Under appropriate conditions, ES cells can form embryoid bodies (EBs) and subsequent differentiation into cardiacmyocytes (CMs) that retain the function of excitability and spontaneous contractions (Wobus et al., 1991) (Maltsev et al., 1994). These spontaneously beating cells contained in EBs have almost the same ion channels that control pacemaker function in the heart (He et al., 2003) (Yanagi et al., 2007). Although multipotent progenitors have previously been shown to give rise to CMs, smooth muscle, and endothelial cells, the mechanism governing the generation of large numbers of differentiated progeny remains poorly understood. Current research indicates that the level of differentiation is low and that few cultured EBs will ultimately convert into functional CMs (Norstrom et al., 2006). The potential use of ES cells to replace functional loss of particular tissues may depend on efficient differentiation protocols to derive tissue-specific cells. By manipulating the culture conditions in which ES cells differentiate, it has been possible to control and restrict the differentiation pathways and thereby generate cultures enriched in lineage-specific cells in vitro. Regulation of multipotent cardiac progenitor cell expansion and subsequent differentiation into CMs, smooth muscle or endothelial cells is a fundamental aspect of basic cardiovascular biology and cardiac regenerative medicine. More recently, direct reprogramming of adult somatic cells to become pluripotent ES-like cells (a.k.a. induced pluripotent stem cells, iPS cells) has been achieved. The cardiogenic potential of iPS cells is comparable to that of ES cells and that iPS-derived CMs (iPS-CMs) possess all fundamental functional elements of a typical cardiac cell, including spontaneous beating, hormonal regulation, cardiac ion channel expression and contractility. Therefore, iPS-CMs can be regarded as a potentially valuable source of cells for in vitro studies and cellular cardiomyoplasty (Pfannkuche et al., 2009). The availability of human ES cells and iPS cells, and their successful differentiation into genuine human cardiac cells have enabled researchers to gain novel insights into the early development of the human heart as well as to pursue the revolutionary paradigm of heart regeneration.

¹ The first 2 authors contributed equally to this work.

2. Embryoid body formation

There are two major ways for EB from ES cells in vitro: suspension culture and hanging drop methods. In suspension culture, ES cells will differentiate into aggregates known as EBs in a manner similar to the early embryo. Suspension methods allow spontaneous aggregation of EBs but usually give rise to heterogeneous cell clusters. The heterogeneous size and shape of EBs resulting from suspension culture can influence their differentiation potential. Hanging drop methods can provide relatively uniform EB size but technically challenge by limited number of EBs for characterization. Recently, other methods such as using spinner flasks and bioreactors for stirred-suspension culture have been utilized. Enhanced growth of EBs in spinner flasks has been reported due to effective nutrient and oxygen supply. In addition to stirred-suspension culture for scalable production of EBs can provide a readily available source of CMs (Lecina et al., 2010). These strategies have been shown to be advantageous compared to conventional suspension method due to their ability to control EB-EB interactions.

Without induced differentiation, the differentiation level is low and that few cultured EBs will ultimately convert into functional CMs. Kehat et al. (Kehat et al., 2001) cultured human ES cells in suspension and plated to form aggregates termed EBs. Spontaneously contracting Cells appeared in only 8.1% of those EBs. Controlling the differentiating pathways permitting efficient generation of more mature and functional cells for basic studies or cardiac repair applications is a pressing need. As molecular mechanisms and signaling pathways leading to efficient differentiation from ES cells have not been understood and well-summarized, the potential factors that impact CM differentiation from ES cells include cell factors, drugs, hormone, culture method, and extracellular matrix.

3. Cell factors and CM differentiation

Schuldiner et al. (Schuldiner et al., 2000) examined the potential of eight growth factors including basic fibroblast growth factor (bFGF), transforming growth factor beta1 (TGF-beta1), activin-A, bone morphogenic protein 4 (BMP-4), hepatocyte growth factor (HGF), epidermal growth factor (EGF), beta nerve growth factor (β NGF), and retinoic acid to direct the differentiation of human ES-derived cells in vitro. They found that the EBs differentiate selectively into mesodermal, endodermal, or ectodermal lineages. However, these studies did not result in homogeneous differentiation of ES cells.

Many differentiating factors, including hepatocyte growth factor (HGF), transforming growth factor beta1 (TGF- β 1), bone morphogenic protein (BMP)-2/4, and fibroblast growth factor (FGF) have been investigated in attempts to improve the efficiency of specific CM differentiation processes in mouse or human ES cells (Gassanov et al., 2004) (Roggia et al., 2007) (Schuldiner et al., 2000) (Ronca et al., 2009). These investigations have had some early encouraging results, but pluripotency and cellular differentiation are intricate biological processes that are coordinately regulated by a complex set of factors and epigenetic regulators, which need increasing research aiming to understand the molecular mechanisms that regulate stem cell differentiation.

Growth factor signaling is required for cellular differentiation, tissue morphogenesis, and tissue homeostasis. Wnt proteins are one important family of growth factors and its signaling is an important regulator of differentiation and morphogenesis that can also control stem cell fates. Tran et al. (Tran et al., 2009) found that mesendoderm formation and

CM differentiation were enhanced by early and transient treatment of human ES cells with Wnt3a. The induction of mesoderm and subsequent cardiac differentiation from human ES cells requires fine-tuned cross talk between activin A/BMP4 and Wnt/beta-catenin pathways (Paige et al., 2010). Cripto is one of epidermal growth factors and its signaling pathway is recently reported as essential role for cardiac myogenesis in ES cells. D'Aniello et al. (D'Aniello et al., 2009) demonstrated that APJ/apelin in the Cripto signaling pathway governs mesoderm patterning and CM differentiation via activation of mitogen-activated protein kinase/p70S6 through coupling to a Go/Gi protein. Hypoxia failed to induce differentiation of mouse ES cells into CMs in the absence of Cripto-1 expression, demonstrating that Cripto-1 is required for hypoxia to fully differentiate mouse ES cells into CMs (Bianco et al., 2009). Phosphorylation of fibroblast growth factor receptor-1 is also reported as essential process required for CM differentiation in ES cells (Ronca et al., 2009). However, the differentiation of ES cells inevitably results in a heterogeneous mixture of cell types present in EBs. It would be more difficult to transform these into a homogenous population of CMs or to stop their differentiation at the functional CM stage. Neuregulin (NRG)-1beta/ErbB signaling regulates the ratio of nodal- to working-type cells in differentiating human ES cell-CM cultures and presumably functions similarly during early human heart development. By manipulating NRG-1beta/ErbB signaling, it will be possible to generate preparations of enriched working-type CMs (Zhu et al., 2010). Calreticulin may have a housekeeping role to play in mature CMs as well as during cardiomyogenesis. Calreticulin, an ER Ca (2+) storage protein, is a crucial regulator of cardiomyogenesis whose presence is required for controlled CM development from ES cells (Papp et al., 2009). Sik1 (salt inducible kinase 1), a serine/threonine kinase that belongs to the stress- and energy-sensing AMP-activated protein kinase family, involves in cardiac cell differentiation and/or heart development. Romito et al. (Romito et al., 2010) studied the role of sik1 in cardiac differentiation and found that sik1-mediated effects are specific for cardiomyogenesis regulating cardiomyoblast cell cycle exit toward terminal differentiation. MicroRNAs are a newly discovered endogenous class of small noncoding RNAs that play important posttranscriptional regulatory roles by targeting messenger RNAs for cleavage or translational repression. microRNAs as important transcriptional regulators may provide a new means of manipulating stem cell fate (Sartipy et al., 2009). By modulating miR-1 and -499 expression levels, human ES cells function can be altered and differentiation directed, thereby enhancing cardiomyogenic differentiation (Sluijter et al., 2010).

4. Drugs used for the CM differentiation of embryonic stem cells

Dimethyl sulfoxide (DMSO), 5-azacytidine, retinoic Acid (RA), ascorbic acid have been investigated in attempts to improve the efficiency of CM differentiation processes in mouse or human ES cells (Paquin et al., 2002) (Yoon et al., 2006) (Drab et al., 1997) (Takahashi et al., 2003). Recently, the synergy of these drugs in inducing ES cell differentiation into matured and functional CMs is quite attractive. Chan et al. (Chan et al., 2009) have investigated Salvianolic acid B-vitamin C synergy in cardiac differentiation from ES cells and found that Salvianolic acid B (saB)- ascorbic acid synergy improves ES cell differentiation into CMs. Recently, accumulating evidence points to reactive oxygen species (ROS) as important signaling molecules for CM differentiation from ES cells. Endogenous ROS control is important for CM formation from ES cells (Crespo et al., 2010). Nitric oxide (NO) has been shown to promote ES cell differentiation by increasing both the number and the size of

beating foci in EB outgrowths (Kanno et al., 2004). Exogenous electric fields have been implied in CM differentiation of mouse ES cells and the generation of ROS, which plays a role in CM differentiation of human ES cells, through mechanisms associated with the intracellular generation of ROS (Serena et al., 2009).

5. Hormones used for the CM differentiation from embryonic stem cells

Recent researches indicate there are some hormone receptors existing in ES cells, so hormone used as inductor to promote the CM differentiation from ES cells receives increasing attention. ES cells expressed cell surface kappa opioid receptors. The prodynorphin gene and its product, dynorphin B, have been found to promote cardiogenesis in embryonic cells by inducing the expression of GATA-4 and Nkx-2.5, two transcription factor-encoding genes essential for cardiogenesis (Ventura et al., 2003). Oxytocin receptor was discovered in undifferentiated ES cells and derived differentiated cells, which plays an important role in cardiogenesis by promoting CM differentiation. Treatment with oxytocin improves the EBs with spontaneous contraction, but has no effect on ultrastructural characteristics of CMs in any stage of development (Paquin et al., 2002) (Hatami et al., 2007). Thyroid hormone is essential for normal cardiac development and function, Lee et al. (Lee et al., 2010) showed that Thyroid (3) supplementation promotes cardiac differentiation of ES cells and enhances maturation of electrophysiological, as well as calcium homeostasis, properties of ES cell-derived CMs.

6. Co-culture differentiation

Although progress has been made towards differentiating stem cells to specific cell lineages, the efficiency is often poor and the number of cells generated is not suitable for therapeutic usage. Recent studies demonstrated that controlling the stem cell microenvironment can influence differentiation. As the differentiation of ES cells closes the development of the embryonic heart (Banach et al., 2003), factors that contribute to essential functions during early embryogenesis are expected to be involved in the formation of EBs (Behfar et al., 2002). However, the precise growth factor combinations that enhance cell differentiation in ES cells are unclear (Schuldiner et al., 2000). Consequently, ES cells are co-cultured with special cells or conditioned media to promote differentiation. For example, when ES cells are co-cultured with visceral-endoderm-like (END-2) cells, the majority (>90%) of the ES -CMs have a phenotype similar to fetal ventricular cells (Mummery et al., 2003). The efficiency of cardiogenic differentiation in ES cells can be readily enhanced by a culture medium that has been conditioned by END-2 cells (Graichen et al., 2008). Similarly, when medium conditioned by mouse embryo fibroblasts is used, the homogeneity of beating EBs can be significantly improved (Burridge et al., 2007).

The niche in which stem cells reside and differentiate is a complex physicochemical microenvironment that regulates cell function. Local microenvironments are considered to be the key inducers in directing the site-specific differentiation of ES cells. Recently, it is reported that endothelial cell play an essential role in facilitating CM differentiation from pluripotent stem cells and regulate regeneration of CMs via EphB4 signaling (Chen et al., 2010). Nevertheless, the effect and the mechanism of the cardiac microenvironment on the development of CM differentiation and EB growth have not yet been systematically studied. We developed a novel protocol to generate functional CMs from ES cells by an in vitro

indirect co-culture inducing strategy that looks promising for tissue engineering applications (fig.1). The propagation and CM differentiation of an ES cell line were studied in prolonged culture in this system (fig. 2). ES cells cultured on membranes by indirect co-culture with native cardiac cells were significantly enhanced ES cells to differentiate into CMs that possessed expression of cardiac specific genes and functions of excitability and




Fig. 1. The indirect co-culture system was used for CM differentiation from mouse ES cells.




Fig. 2. The differentiation of embryonic stem cells (ES cells).
(A) The percentage of embryoid bodies (EBs) with spontaneously contracting areas in control and co-culture groups during plating culture.
(B) The in vitro differentiation process of ES cells in co-culture system.




Fig. 3. The expression of cardiac markers in ES cells. (A) OCT4, GATA4, Nkx2.5, ANF and CX43 expressions were almost increased in the co-culture system. (B),(C) Real time-PCR was performed to detect mRNA expressions of GATA and ANF in prolonged time course. *: $P < 0.05$, **: $P < 0.01$. (D),(E) the protein expression of cardiac troponin I (cTnI) and connexin 43 (Cx43) in co-culture system.

spontaneous contractions (fig. 3). This co-culture system is a significant advance in ES cells culture methods, providing possibility to efficiently control the differentiation of ES cells and to more reliably obtain a large number of more mature and homogenous CMs for large-scale tissue engineering applications and other stem cell-based regenerative medicine (Ou et al., 2009a).

7. 2D vs. 3D differentiation

Previously the most common model in vitro for cell research has been 2D monolayer culture. Even though EB has 3D structures, the researches on the differentiation of ES cells are mainly based on 2D cultured systems. However, these 2D cultured systems don't mimic the physiological environment in vivo and may lead to low differentiated level of ES cells. Significant differences were found in the differentiation efficiency of ES cells when they were cultured in 2D and 3D environment (Liu et al., 2006).

The extracellular microenvironment for 3D differentiation plays a significant role in regulating ES cells to differentiate into special lineages, as well as in cell migration and proliferation (Philp et al., 2005) (Chen et al., 2007). The extracellular matrix is in close contact with cells and involved in their maintenance and regulation. The mechanical and chemical signals (e.g., integrin signals) elicited by the extracellular matrix regulate the activities of cytoplasmic kinases, receptors for growth factor and ion channels, impacting differentiation of stem cells. Extracellular matrix proteins independently trigger differentiation of human mesenchymal stem cells and that differentiation in this context can be guided down multiple lineages using the same Extracellular matrix protein stimulus (Santiago et al., 2009). A new scalable bioprocessing system as a scalable platform for CM production has been developed (Lecina et al., 2010). Use of a 3-D cuboidal microwell system to culture human ES cells in colonies of defined dimensions, 100-500 microm in lateral dimensions and 120 microm in depth, enabled formation of more uniform-sized EBs. The regulation of microwell-engineered EB size can be used for more efficient and reproducible formation of human ES cell-CMs (Mohr et al., 2010). In addition, proliferation of stem cell-derived CMs appears to be regulated by microtopography through tension-generation of contractility in the third-dimension (Biehl et al., 2009).

Bioreactors, recent methods to achieve CM differentiation by engineering the stem cell microenvironment, are used to control the differentiation and produce large numbers of desired cells. Based on bioreactors, it is very likely to control the differentiation of ES cells: (1) biomaterials technology, biomaterials with different growth factors or morphogenetic factors delivery systems can be utilized to mimic embryogenic process, our unpublished data demonstrates that specific factors released from biomaterials via diffusion can enhance long-term survival and differentiation of ES cells, and (2) the use of bioreactors, cultivation in rotating bioreactors can promote and maintain CMs electrophysiology and molecular properties (Bursac et al., 2003).

8. The potential applications

The availability of ES and iPS cells and their successful differentiation into genuine human cardiac cells have enabled researchers to gain novel insights into the early development of the human heart as well as to pursue the revolutionary paradigm of heart regeneration. Their potential applications for ES cells in cardiac research area include developmental biology, functional genomics, pharmacological testing, cell therapy, organ regeneration, and biological pacemaker.

8.1 Pharmacological testing

Recent withdrawals of prescription drugs from clinical use because of unexpected side effects on the heart have highlighted the need for more reliable cardiac safety pharmacology assays. Human or mouse ES cell-derived CMs serve together as a valuable model for drug safety screening and advance preclinical drug development. Assays based on human ES cell-derived CMs could complement or potentially replace some of the preclinical cardiac toxicity screening tests currently used for lead optimization and further development of new drugs (Braam et al., 2010) (Liang et al., 2010). Human ES cell-derived CMs have been used to predicate of drug-induced cardiotoxicity, e.g., to study cardioprotective effects of dexamethasone in doxorubicin cardiotoxicity (Farokhpour et al., 2009) (Braam et al., 2010).

8.2 Cell therapy

ES cells, which can be differentiated into cardiac progenitors and CMs, represent a candidate cell source for cardiac cell therapy. However, it is not known what specific cell type or condition is the most appropriate for transplantation. It is reported that transplanted mouse ES cells in the infarcted heart inhibit apoptosis, fibrosis, and hypertrophy, thereby reducing adverse remodeling, resulting in the improvement of cardiac function (Singla et al., 2007) (Singla and McDonald, 2007) (Xie et al., 2007). Several recent studies have demonstrated that human ES cell-derived CMs survive after transplantation into infarcted rodent hearts, form stable cardiac implants, and result in preserved contractile function. To investigate the ischemic environment of host myocardium affects transplanted pluripotent cells, van Laake et al. (van Laake et al., 2009) cultured mouse ES cells in medium containing ischemic myocardial interstitial fluid (iMIF) and found that the ischemic/infarcted environment is favorable to stem cell-mediated angiogenesis, but hostile to cardiac myogenesis. These findings indicated mouse ES cell-mediated improvement of cardiac function after transplantation of pluripotent cells do not reflect remuscularization. Although cell transplantation has modestly improved cardiac function, major challenges including increasing cell survival, engraftment, and functional integration with host tissue.

8.3 Cardiac muscle regeneration

Tissue-engineered cardiac muscle transplantation may have advantages over direct cell transplantation or replacement therapy for myocardial defect. The use of engineered heart tissue as a model system to accelerate development of cardiac cell therapy strategies has been demonstrated (Song et al., 2010). Human ES cell-derived CMs alone or with human endothelial cells (human umbilical vein endothelial cells) and embryonic fibroblasts (triculture constructs) were seeded onto biodegradable porous scaffolds. This tissue-engineered human vascularized cardiac muscle have been established in vitro and transplanted in vivo to form stable grafts (Lesman et al., 2010b).

Effective engineering of viable thick complex tissue-constructs requires intense vascularization. More recently, a beating human cardiac muscle-construct containing an endothelial network was established by co-culturing human embryonic stem cell-derived-CMs, fibroblasts, and endothelial cells within biodegradable scaffolds (Lesman et al., 2010a). The success of cardiac muscle regeneration and transplantation is dependent on a combination of several factors, such as: 1) the formation of new blood vessels, 2) the release of pro-survival, pro-angiogenic and anti-inflammatory factors (paracrine effect), and 3) the functional contribution of CMs and functional integration with host tissue.

Components of the extracellular matrix are considered to be important physiological regulators and provide mechanical cues, direct differentiation and improve cell engraftment into damaged tissue. However, there are also adverse effects of scaffold materials, e.g. necrosis at the tissue core, low vascularization, and poor survival after transplantation. Scaffold-free for vascularized human cardiac muscle tissue that markedly improved viability after transplantation has been developed (Stevens et al., 2009).

8.4 Biological pacemaker

Sudden cardiac death due to abnormal heart rhythm from sick sinus syndrome kills millions of people each year, the reduction of the morbidity and mortality depends on how we can restore the generation of the cardiac impulse effectively. A conventional approach is implantation of electronic pacemakers, which are commonly used to treat cardiac impulse generation defects. However, there are many shortcomings for electronic pacemakers in clinical applications, such as the limited battery life, lack of catecholamine responsiveness, and associating with inconvenience in daily life (Rosen et al., 2004). Biological cardiac pacemaker, mimicking the sinoatrial node (SA-node), has been served as a promising way to restore the generation of the cardiac impulse for better alternative to the present routine.

ES cells can be induced to differentiate into CMs with excitability and spontaneous contraction activities (Wobus et al., 1991) (Maltsev et al., 1994), which raises the prospect of the probable therapeutic application of ES cells in cardiac pacing. Their use as biological pacemakers has also been explored (Kehat et al., 2004) (Xue et al., 2005) (Menasche, 2004 ; Yanagi et al., 2007). Kehat et al. (Kehat et al., 2004) had discussed the potential of human ES cell-derived CMs to act as a rate-responsive biological pacemaker. The transplanted human ES cell-derived CMs can functionally integrate with other quiescent ventricular cells and pace the heart of swine with complete AV block, as assessed by detailed three-dimensional electrophysiological mapping and histopathological examination. Xue et al.'s work (Xue et al., 2005) was similar with Kehat's. A functional human ES cell-derived pacemaker could be implanted in the left ventricle in vivo and successful spread of membrane depolarization was confirmed from surrounding myocardium in the site of injection.

Nevertheless, the use of ES cells in cardiac pacing is challenged by how to control the differentiation of ES cells and overcome the neoplasia, proarrhythmia or immunogenicity after transplantation. As a potential approach to solve these difficult problems, tissue engineering techniques may provide a precise control on the different cell components of multicellular aggregates and the forming construct with defined architectures and function properties (Ou et al., 2009b). For any biological pacemaker to be considered a potential medical therapy, it must functionally integrate with the heart and provide an impulse initiation enough and steady in the conducting system to ensure physiological activation of the heart. The applications of tissue engineering techniques not only provide a 3D environment for cells growth and expanding, but also provide structural support for higher order tissue organization and remodeling. The combined interactions among ES cell-derived pacemaker cells, supporting cells and matrices may result in a steady functional unit to induce rhythmic electrical and contractile activities and completely reproduce pacemaker properties.

9. The challenges in stem cell research

These investigations for ES cell differentiation have had some early encouraging results, but pluripotency and cellular differentiation are intricate biological processes that are coordinately regulated by a complex set of factors and epigenetic regulators, which need increasing research aiming to understand the molecular mechanisms that regulate stem cell differentiation. The major direction of human ES cell use is derivation of a specific differentiated progeny, which has lower proliferative potential and immune privilege, yet poses fewer risks. There is report that immaturity of the sarcoplasmic reticulum and the beta-adrenergic response can be found in CMs from ES Cells and iPS cells (Xi et al., 2010). The heterogeneity in electrical properties of the human ES cell-CMs is exist (Pekkanen-Mattila et al., 2010).

Pluripotent stem cell biology and technology is in need of further investigation and development. The development of efficient and reproducible culture systems for culturing ES cells in complete xeno-free conditions to reduce the risk of cross-transfer of pathogens without loss pluripotency is an essential pre-requisite for regenerative medicine. Synthetic, xeno-free, scalable surfaces that support the self-renewal and differentiation of ES Cells and iPS cells will be useful for both research purposes and development of cell therapies (Melkounian et al., 2010).

Efficiently controlling the differentiation of ES Cells to produce more mature and homogenous CMs is currently the most challenging task. Thus, a future challenge will be to design strategies that eventually may allow the cells to reach a higher degree of maturation in vitro.

The recent development of reprogramming of differentiated human somatic cells to iPS cells should overcome ethics obstacles and facilitate clinical applications of stem cells. The most advantages of reprogramming is that it allows the establishment of patient- and disease-specific in vitro models of human hereditary diseases for pathophysiologic and developmental studies. However, although human ES cells and human iPS cells have been shown to share a number of similarities, there are still differences electrophysiology properties between human ES cells and human iPS cells (Jiang et al., 2010). It has been showed that foreign genes were silenced or removed after reprogramming, but those approaches have low reprogramming efficiency, and either leave residual vector sequences,

or require tedious steps. Whether reprogramming methods can be improved will depend on a better understanding on the molecular cell biology of pluripotent stem cells.

10. References


- Banach K., Halbach M.D., Hu P., Hescheler J. & Egert U. (2003). Development of electrical activity in cardiac myocyte aggregates derived from mouse embryonic stem cells. *Am J Physiol Heart Circ Physiol*, 284, H2114-2123
- Behfar A., Zingman L.V., Hodgson D.M., Rauzier J.M., Kane G.C., Terzic A. & Puceat M. (2002). Stem cell differentiation requires a paracrine pathway in the heart. *Faseb J*, 16, 1558-1566
- Bianco C., Cotten C., Lonardo E., Strizzi L., Baraty C., Mancino M., Gonzales M., Watanabe K., Nagaoka T., Berry C., Arai A.E., Minchiotti G. & Salomon D.S. (2009). Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. *Am J Pathol*, 175, 2146-2158
- Biehl J.K., Yamanaka S., Desai T.A., Boheler K.R. & Russell B. (2009). Proliferation of mouse embryonic stem cell progeny and the spontaneous contractile activity of cardiomyocytes are affected by microtopography. *Dev Dyn*, 238, 1964-1973
- Braam S.R., Tertoolen L., van de Stolpe A., Meyer T., Passier R. & Mummery C.L. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. *Stem Cell Res*, 4, 107-116
- Burridge P.W., Anderson D., Priddle H., Barbadillo Munoz M.D., Chamberlain S., Allegrucci C., Young L.E. & Denning C. (2007). Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. *Stem Cells*, 25, 929-938
- Bursac N., Papadaki M., White J.A., Eisenberg S.R., Vunjak-Novakovic G. & Freed L.E. (2003). Cultivation in rotating bioreactors promotes maintenance of cardiac myocyte electrophysiology and molecular properties. *Tissue Eng*, 9, 1243-1253
- Chan S.S., Chen J.H., Hwang S.M., Wang I.J., Li H.J., Lee R.T. & Hsieh P.C. (2009). Salvianolic acid B-vitamin C synergy in cardiac differentiation from embryonic stem cells. *Biochem Biophys Res Commun*, 387, 723-728
- Chen K., Bai H., Arzigian M., Gao Y.X., Bao J., Wu W.S., Shen W.F., Wu L. & Wang Z.Z. (2010). Endothelial cells regulate cardiomyocyte development from embryonic stem cells. *J Cell Biochem*, 111, 29-39
- Chen S.S., Fitzgerald W., Zimmerberg J., Kleinman H.K. & Margolis L. (2007). Cell-cell and cell-extracellular matrix interactions regulate embryonic stem cell differentiation. *Stem Cells*, 25, 553-561
- Crespo F.L., Sobrado V.R., Gomez L., Cervera A.M. & McCreath K.J. (2010). Mitochondrial reactive oxygen species mediate cardiomyocyte formation from embryonic stem cells in high glucose. *Stem Cells*, 28, 1132-1142
- D'Aniello C., Lonardo E., Iaconis S., Guardiola O., Liguoro A.M., Liguori G.L., Autiero M., Carmeliet P. & Minchiotti G. (2009). G protein-coupled receptor APJ and its ligand apelin act downstream of Cripto to specify embryonic stem cells toward the cardiac lineage through extracellular signal-regulated kinase/p70S6 kinase signaling pathway. *Circ Res*, 105, 231-238
- Drab M., Haller H., Bychkov R., Erdmann B., Lindschau C., Haase H., Morano I., Luft F.C. & Wobus A.M. (1997). From totipotent embryonic stem cells to spontaneously

- contracting smooth muscle cells: a retinoic acid and db-cAMP in vitro differentiation model. *Faseb J*, 11, 905-915
- Farokhpour M., Karbalaie K., Tanhaei S., Nematollahi M., Etebari M., Sadeghi H.M., Nasr-Esfahani M.H. & Baharvand H. (2009). Embryonic stem cell-derived cardiomyocytes as a model system to study cardioprotective effects of dexamethasone in doxorubicin cardiotoxicity. *Toxicol In Vitro*, 23, 1422-1428
- Gassanov N., Er F., Zagidullin N. & Hoppe U.C. (2004). Endothelin induces differentiation of ANP-EGFP expressing embryonic stem cells towards a pacemaker phenotype. *Faseb J*, 18, 1710-1712
- Graichen R., Xu X., Braam S.R., Balakrishnan T., Norfiza S., Sieh S., Soo S.Y., Tham S.C., Mummery C., Colman A., Zweigerdt R. & Davidson B.P. (2008). Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. *Differentiation*, 76, 357-370
- Hatami L., Valojerdi M.R. & Mowla S.J. (2007). Effects of oxytocin on cardiomyocyte differentiation from mouse embryonic stem cells. *Int J Cardiol*, 117, 80-89
- He J.Q., Ma Y., Lee Y., Thomson J.A. & Kamp T.J. (2003). Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. *Circ Res*, 93, 32-39
- Jiang P., Rushing S.N., Kong C.W., Fu J., Lieu D.K., Chan C.W., Deng W. & Li R.A. (2010). Electrophysiological properties of human induced pluripotent stem cells. *Am J Physiol Cell Physiol*, 298, C486-495
- Kanno S., Kim P.K., Sallam K., Lei J., Billiar T.R. & Shears L.L., 2nd. (2004). Nitric oxide facilitates cardiomyogenesis in mouse embryonic stem cells. *Proc Natl Acad Sci U S A*, 101, 12277-12281
- Kehat I., Kenyagin-Karsenti D., Snir M., Segev H., Amit M., Gepstein A., Livne E., Binah O., Itskovitz-Eldor J. & Gepstein L. (2001). Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. *J Clin Invest*, 108, 407-414
- Kehat I., Khimovich L., Caspi O., Gepstein A., Shofti R., Arbel G., Huber I., Satin J., Itskovitz-Eldor J. & Gepstein L. (2004). Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. *Nat Biotechnol*, 22, 1282-1289
- Lecina M., Ting S., Choo A., Reuveny S. & Oh S. (2010). Scalable Platform for Human Embryonic Stem Cell Differentiation to Cardiomyocytes in Suspended Microcarrier Cultures. *Tissue Eng Part C Methods*, Aug 28. [Epub ahead of print]
- Lee Y.K., Ng K.M., Chan Y.C., Lai W.H., Au K.W., Ho C.Y., Wong L.Y., Lau C.P., Tse H.F. & Siu C.W. (2010). Triiodothyronine Promotes Cardiac Differentiation and Maturation of Embryonic Stem Cells via the Classical Genomic Pathway. *Mol Endocrinol*, 24, 1728-1736
- Lesman A., Gepstein L. & Levenberg S. (2010a). Vascularization shaping the heart. *Ann N Y Acad Sci*, 1188, 46-51
- Lesman A., Habib M., Caspi O., Gepstein A., Arbel G., Levenberg S. & Gepstein L. (2010b). Transplantation of a tissue-engineered human vascularized cardiac muscle. *Tissue Eng Part A*, 16, 115-125
- Liang H., Matzkies M., Schunkert H., Tang M., Bonnemeier H., Hescheler J. & Reppel M. (2010). Human and murine embryonic stem cell-derived cardiomyocytes serve

- together as a valuable model for drug safety screening. *Cell Physiol Biochem*, 25, 459-466
- Liu H., Lin J. & Roy K. (2006). Effect of 3D scaffold and dynamic culture condition on the global gene expression profile of mouse embryonic stem cells. *Biomaterials*, 27, 5978-5989
- Maltsev V.A., Wobus A.M., Rohwedel J., Bader M. & Hescheler J. (1994). Cardiomyocytes differentiated in vitro from embryonic stem cells developmentally express cardiac-specific genes and ionic currents. *Circ Res*, 75, 233-244
- Melkounian Z., Weber J.L., Weber D.M., Fadeev A.G., Zhou Y., Dolley-Sonneville P., Yang J., Qiu L., Priest C.A., Shogbon C., Martin A.W., Nelson J., West P., Beltzer J.P., Pal S. & Brandenberger R. (2010). Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. *Nat Biotechnol*, 28, 606-610
- Menasche P. (2004). Embryonic stem cells pace the heart. *Nat Biotechnol*, 22, 1237-1238
- Mohr J.C., Zhang J., Azarin S.M., Soerens A.G., de Pablo J.J., Thomson J.A., Lyons G.E., Palecek S.P. & Kamp T.J. (2010). The microwell control of embryoid body size in order to regulate cardiac differentiation of human embryonic stem cells. *Biomaterials*, 31, 1885-1893
- Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., van der Heyden M., Opthof T., Pera M., de la Riviere A.B., Passier R. & Tertoolen L. (2003). Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. *Circulation*, 107, 2733-2740
- Norstrom A., Akesson K., Hardarson T., Hamberger L., Bjorquist P. & Sartipy P. (2006). Molecular and pharmacological properties of human embryonic stem cell-derived cardiomyocytes. *Exp Biol Med* (Maywood), 231, 1753-1762
- Ou D.B., Chen R., Liu X.T., Guo J.J., Wang H.T. & Zheng Q.S. (2009a). Controlling the in vitro differentiation of embryonic stem cells for myocardial tissue engineering applications. *Cell Biol Int*, Sep 15. [Epub ahead of print]
- Ou D.B., Lang H.J., Chen R., Liu X.T. & Zheng Q.S. (2009b). Using embryonic stem cells to form a biological pacemaker via tissue engineering technology. *Bioessays*, 31, 246-252
- Paige S.L., Osugi T., Afanasiev O.K., Pabon L., Reinecke H. & Murry C.E. (2010). Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. *PLoS One*, 5, e11134
- Papp S., Dziak E. & Opas M. (2009). Embryonic stem cell-derived cardiomyogenesis: a novel role for calreticulin as a regulator. *Stem Cells*, 27, 1507-1515
- Paquin J., Danalache B.A., Jankowski M., McCann S.M. & Gutkowska J. (2002). Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. *Proc Natl Acad Sci U S A*, 99, 9550-9555
- Pekkanen-Mattila M., Chapman H., Kerkela E., Suuronen R., Skottman H., Koivisto A.P. & Aalto-Setälä K. (2010). Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype. *Exp Biol Med* (Maywood), 235, 522-530
- Pfannkuche K., Liang H., Hannes T., Xi J., Fatima A., Nguemo F., Matzkies M., Wernig M., Jaenisch R., Pillekamp F., Halbach M., Schunkert H., Saric T., Hescheler J. & Reppel

- M. (2009). Cardiac myocytes derived from murine reprogrammed fibroblasts: intact hormonal regulation, cardiac ion channel expression and development of contractility. *Cell Physiol Biochem*, 24, 73-86
- Philp D., Chen S.S., Fitzgerald W., Orenstein J., Margolis L. & Kleinman H.K. (2005). Complex extracellular matrices promote tissue-specific stem cell differentiation. *Stem Cells*, 23, 288-296
- Roggia C., Ukena C., Bohm M. & Kilter H. (2007). Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase. *Exp Cell Res*, 313, 921-930
- Romito A., Lonardo E., Roma G., Minchiotti G., Ballabio A. & Cobellis G. (2010). Lack of sik1 in mouse embryonic stem cells impairs cardiomyogenesis by down-regulating the cyclin-dependent kinase inhibitor p57kip2. *PLoS One*, 5, e9029
- Ronca R., Gualandi L., Crescini E., Calza S., Presta M. & Dell'Era P. (2009). Fibroblast growth factor receptor-1 phosphorylation requirement for cardiomyocyte differentiation in murine embryonic stem cells. *J Cell Mol Med*, 13, 1489-1498
- Rosen M.R., Brink P.R., Cohen I.S. & Robinson R.B. (2004). Genes, stem cells and biological pacemakers. *Cardiovasc Res*, 64, 12-23
- Santiago J.A., Pogemiller R. & Ogle B.M. (2009). Heterogeneous differentiation of human mesenchymal stem cells in response to extended culture in extracellular matrices. *Tissue Eng Part A*, 15, 3911-3922
- Sartipy P., Olsson B., Hyllner J. & Synnergren J. (2009). Regulation of 'stemness' and stem cell differentiation by microRNAs. *IDrugs*, 12, 492-496
- Schuldiner M., Yanuka O., Itskovitz-Eldor J., Melton D.A. & Benvenisty N. (2000). Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. *Proc Natl Acad Sci U S A*, 97, 11307-11312
- Serena E., Figallo E., Tandon N., Cannizzaro C., Gerecht S., Elvassore N. & Vunjak-Novakovic G. (2009). Electrical stimulation of human embryonic stem cells: cardiac differentiation and the generation of reactive oxygen species. *Exp Cell Res*, 315, 3611-3619
- Singla D.K., Lyons G.E. & Kamp T.J. (2007). Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. *Am J Physiol Heart Circ Physiol*, 293, H1308-1314
- Singla D.K. & McDonald D.E. (2007). Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells. *Am J Physiol Heart Circ Physiol*, 293, H1590-1595
- Sluijter J.P., van Mil A., van Vliet P., Metz C.H., Liu J., Doevendans P.A. & Goumans M.J. (2010). MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. *Arterioscler Thromb Vasc Biol*, 30, 859-868
- Song H., Yoon C., Kattman S.J., Dengler J., Masse S., Thavaratnam T., Gewarges M., Nanthakumar K., Rubart M., Keller G.M., Radisic M. & Zandstra P.W. (2010). Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue. *Proc Natl Acad Sci U S A*, 107, 3329-3334
- Stevens K.R., Kreutziger K.L., Dupras S.K., Korte F.S., Regnier M., Muskheli V., Nourse M.B., Bendixen K., Reinecke H. & Murry C.E. (2009). Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. *Proc Natl Acad Sci U S A*, 106, 16568-16573

- Takahashi T., Lord B., Schulze P.C., Fryer R.M., Sarang S.S., Gullans S.R. & Lee R.T. (2003). Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. *Circulation*, 107, 1912-1916
- Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S. & Jones J.M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science*, 282, 1145-1147
- Tran T.H., Wang X., Browne C., Zhang Y., Schinke M., Izumo S. & Burcin M. (2009). Wnt3a-induced mesoderm formation and cardiomyogenesis in human embryonic stem cells. *Stem Cells*, 27, 1869-1878
- van Laake L.W., Passier R., den Ouden K., Schreurs C., Monshouwer-Kloots J., Ward-van Oostwaard D., van Echteld C.J., Doevendans P.A. & Mummery C.L. (2009). Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. *Stem Cell Res*, 3, 106-112
- Ventura C., Zinellu E., Maninchedda E., Fadda M. & Maioli M. (2003). Protein kinase C signaling transduces endorphin-primed cardiogenesis in GTR1 embryonic stem cells. *Circ Res*, 92, 617-622
- Wobus A.M., Wallukat G. & Hescheler J. (1991). Pluripotent mouse embryonic stem cells are able to differentiate into cardiomyocytes expressing chronotropic responses to adrenergic and cholinergic agents and Ca²⁺ channel blockers. *Differentiation*, 48, 173-182
- Xi J., Khalil M., Shishechian N., Hannes T., Pfannkuche K., Liang H., Fatima A., Haustein M., Suhr F., Bloch W., Reppel M., Saric T., Wernig M., Janisch R., Brockmeier K., Hescheler J. & Pillekamp F. (2010). Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. *FASEB J*, 24, 2739-2751
- Xie C.Q., Zhang J., Xiao Y., Zhang L., Mou Y., Liu X., Akinbami M., Cui T. & Chen Y.E. (2007). Transplantation of human undifferentiated embryonic stem cells into a myocardial infarction rat model. *Stem Cells Dev*, 16, 25-29
- Xue T., Cho H.C., Akar F.G., Tsang S.Y., Jones S.P., Marban E., Tomaselli G.F. & Li R.A. (2005). Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. *Circulation*, 111, 11-20
- Yanagi K., Takano M., Narazaki G., Uosaki H., Hoshino T., Ishii T., Misaki T. & Yamashita J.K. (2007). Hyperpolarization-activated cyclic nucleotide-gated channels and T-type calcium channels confer automaticity of embryonic stem cell-derived cardiomyocytes. *Stem Cells*, 25, 2712-2719
- Yoon B.S., Yoo S.J., Lee J.E., You S., Lee H.T. & Yoon H.S. (2006). Enhanced differentiation of human embryonic stem cells into cardiomyocytes by combining hanging drop culture and 5-azacytidine treatment. *Differentiation*, 74, 149-159
- Zhu W.Z., Xie Y., Moyes K.W., Gold J.D., Askari B. & Laflamme M.A. (2010). Neuregulin/ErbB Signaling Regulates Cardiac Subtype Specification in Differentiating Human Embryonic Stem Cells. *Circ Res*,



Embryonic Stem Cells: The Hormonal Regulation of Pluripotency and Embryogenesis

Edited by Prof. Craig Atwood

ISBN 978-953-307-196-1

Hard cover, 672 pages

Publisher InTech

Published online 26, April, 2011

Published in print edition April, 2011

Pluripotency is a prerequisite for the subsequent coordinated differentiation of embryonic stem cells into all tissues of the body. This book describes recent advances in our understanding of pluripotency and the hormonal regulation of embryonic stem cell differentiation into tissue types derived from the ectoderm, mesoderm and endoderm.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Dong-Bo Ou, Qiang-Sun Zheng, Yong He, Di Zeng and Ji-Wei Teng (2011). Recent Advances in Controlling Cardiacmyocyte Differentiation from Embryonic Stem Cells, *Embryonic Stem Cells: The Hormonal Regulation of Pluripotency and Embryogenesis*, Prof. Craig Atwood (Ed.), ISBN: 978-953-307-196-1, InTech, Available from: <http://www.intechopen.com/books/embryonic-stem-cells-the-hormonal-regulation-of-pluripotency-and-embryogenesis/recent-advances-in-controlling-cardiacmyocyte-differentiation-from-embryonic-stem-cells>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen